Virtual Event Coverage

Q4 Investor Summit Micro & Small Cap Conference

November 16th – 17th, 2021 - Virtual Event
Q4 Investor Summit Micro & Small Cap Conference

Investor Summit Group's events feature live presentations with Q&A, 1 on 1 meetings, roundtables, workshops, fireside chats and more. Each quarterly summit provides the opportunity to discuss relevant topics in the investment space with quality vetted investors and handpicked executives. With countless interaction possibilities, attendees are brought as close as possible with Investor Summit Group's next-generation networking platform.

For more information visit:
Conference Website

A2Z Smart Technologies Corp. (TSXV: AZ) (OTCQB: AAZZF)

A2Z Smart Technologies Corp. (TSXV:AZ) (OTCQB: AAZZF) creates innovative solutions for complex challenges. A2Z's flagship product is the world's first proven-in-use mobile self-checkout shopping chart. With its user-friendly smart algorithm, touch screen, and computer-vision system, Cust2Mate streamlines the retail shopping experience by automatically scanning purchased products and enabling in-cart payment so that customers can simply "pick & go", and bypass long cashier checkout lines. This results in a more efficient shopping experience for customers, less unused shelf-space and manpower requirements, and advanced command and control capabilities for store managers. Cust2Mate's SAAS-based software solution also provides shelf heatmaps for targeted advertising, direct marketing and special promotions that generate increased revenues and profits for retailers. For more information, visit the company's website at:

Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST)

Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery—all which could help to increase treatment compliance and improve patient outcomes. For more information, visit the company's website at:

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM)

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs not addressed by traditional cancer therapies. Actinium's current clinical pipeline is led by ARCs or Antibody Radiation-Conjugates that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. Actinium's targeted conditioning ARCs seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) has been studied in several hundred patients including in the recently completed, 150-patient, pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. Iomab-ACT, low dose I-131 apamistamab is being studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center. In addition, theyare leaders in the field of Actinium-225 alpha therapies. Actimab-A, their clinical stage CD33 targeting ARC alpha therapy has been studied in nearly 150 patients including their ongoing combination trials with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning their clinical programs is their proprietary AWE (Antibody Warhead Enabling) technology platform. This is where their intellectual property portfolio of over 160 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster their pipeline for strategic purposes. For more information, visit the company's website at:

Adcore Inc. (TSX: ADCO) (OTCQX: ADCOF)

Adcore Inc. (TSX: ADCO) (OTCQX: ADCOF) is empowering entrepreneurs, advertisers, and the future of e-commerce through its advertising management and automation platform. By combining extensive industry knowledge and experience with its proprietary artificial intelligence engine, Adcore offers a unique digital marketing solution that empowers entrepreneurs and advertisers by managing and automating their e-commerce store advertising, and monitoring and analyzing the performance of their advertising budget to ensure maximum Return on Investment. In addition to being named numerous times on Deloitte's Fast 50 Technology list, Adcore is a certified Google Premier Partner, Microsoft Partner, Facebook Partner and TikTok Partner. Established in 2006, the Company employs over fifty people in its headquarters in Tel Aviv, Israel and satellite offices in Toronto, Canada, Melbourne, Australia, Hong Kong and Shanghai, China. For more information, visit the company's website at:

Alimera Sciences (NASDAQ: ALIM)

Alimera Sciences (NASDAQ: ALIM) is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, visit the company's website at:

Alpha Cognition Inc. (TSXV: ACOG) (OTCQB: ACOGF)

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury. ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation. For more information, visit the company's website at:

Amesite Inc. (NASDAQ: AMST)

Amesite Inc. (NASDAQ: AMST) is an ed-tech, SaaS company with the most advanced artificial intelligence driven online learning platform in the industry, providing both content creation and a best-in-class infrastructure for the multi-billion-dollar online learning markets in business and education. For more information, visit the company's website at:

Annovis Bio, Inc. (NYSE: ANVS)

Annovis Bio, Inc. (NYSE: ANVS) is a clinical- stage, drug platform company addressing chronic and acute neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). Annovis' novel approach is to develop drugs that normalize the transport of information within and between nerve cells, called axonal transport. Their drug, ANVS-401, restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. Theyhave an ongoing Phase 2a proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase 2a study in PD patients. For more information visit the company's website at:


AnPac Bio. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection, with 148 issued patents as of June 30, 2021. With one CLIA and CAP registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan's report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The Company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio's CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information visit the company's website at:

ARC Document Solutions, Inc. (NYSE: ARC)

ARC Document Solutions, Inc. (NYSE: ARC) provides a wide variety of document distribution and graphic production services to facilitate communication for professionals in the design, marketing, commercial real estate, construction and related fields. For more information visit the company's website at:

ARCA Biopharma, Inc. (NASDAQ: ABIO)

ARCA Biopharma, Inc. (NASDAQ: ABIO) is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2 clinical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, visit the company's website at:

Artelo Biosciences (NASDAQ: ARTL)

Artelo Biosciences (NASDAQ: ARTL) is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information, visit the company's website at:

Assertio Holdings, Inc. (NASDAQ: ASRT)

Assertio Holdings, Inc. (NASDAQ: ASRT) is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions. For more information, visit the company's website at:


Auddia Inc. (NASDAQ: AUUD) (NASDAQ: AUUDW) is reinventing how consumers engage with audio through the development of a proprietary AI platform for audio and innovative technologies for podcasts. Auddia offers two industry firsts-the ability to listen to any AM/FM radio station with added personalized content and no commercials, as well as podcasts with an interactive digital feed that supports deeper stories and delivers digital revenue to podcasters. Both offerings address large and rapidly growing audiences with strong purchase intent. For more information, visit the company's website at:

Avalon Advanced Materials Inc. (TSX: AVL) (OTCQB: AVLNF)

Avalon Advanced Materials Inc. (TSX: AVL) (OTCQB: AVLNF) is a Canadian mineral development company specializing in sustainably produced materials for clean technology. The Company now has four advanced stage projects, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, cesium and zirconium. Avalon is currently focusing on developing its Separation Rapids Lithium Project near Kenora, Ontario while looking at several new project opportunities, including re-activating its 100%-owned Lilypad Cesium-Tantalum-Lithium Project in northwestern Ontario. Social responsibility and environmental stewardship are corporate cornerstones. For more information, visit the company's website at:

Banxa Holdings Inc. (TSXV: BNXA) (OTCQX: BNXAF)

Banxa Holdings Inc. (TSX-V: BNXA) (OTCQX: BNXAF) (FSE: AC00) Banxa powers the world's largest digital asset platforms by providing payments infrastructure and regulatory compliance across global markets. Banxa's mission and vision is to build the bridge that provides people in every part of the world access to a fairer and more equitable financial system. Banxa is headquartered in Melbourne, Australia, with European headquarters in Amsterdam, the Netherlands. For more information, visit the company's website at:

Basanite Inc. (OTCQB: BASA)

Basanite Inc. (OTCQB: BASA) is a leading manufacturer and market developer of environmentally friendly, high-performance composite products used in concrete reinforcement. Superior to traditional steel elements, Basanite's sustainable products are non-corrosive, lighter, stronger and longer lasting. For more information, visit the company's website at:

Battery Mineral Resources Corp. (TSXV: BMR)

Battery Mineral Resources Corp. (TSXV: BMR) A battery mineral company with high-quality assets providing shareholders exposure to the global mega-trend of electrification and focused on growth through cash-flow, exploration, and acquisitions in the world's top mining jurisdictions. BMR is currently developing the Punitaqui Mining Complex and pursuing the potential near term resumption of operations at the prior producing Punitaqui copper-gold mine. The Punitaqui copper-gold mine most recently produced approximately 21,000 tonnes of copper concentrate in 2019 and is located in the Coquimbo region of Chile. BMR is engaged in the discovery, acquisition, and development of battery metals (cobalt, lithium, graphite, nickel & copper), in North and South America and South Korea with the intention of becoming a premier and sustainable supplier of battery minerals to the electrification marketplace. Battery Mineral Resources is the largest mineral claim holder in the historic Gowganda Cobalt-Silver Camp, Canada and continues to pursue a focused program to build on the recently announced, +1-million-pound high-grade cobalt resource at McAra by testing over 50 high-grade primary cobalt silver-nickel-copper targets. In addition, Battery owns 100% of ESI Energy Services, Inc., also known as Ozzie's, a pipeline equipment rental and sales company with operations in Leduc, Alberta and Phoenix, Arizona. For more information, visit the company's website at:

BeWhere Holdings Inc. (TSXV: BEW) (OTCQB: BEWFF)

BeWhere Holdings Inc. (TSX-V: BEW) (OTCQB: BEWFF) is a Mobile Internet of Things ("M-IoT") solutions company that designs and sells self-powered hardware with sensors and software applications. Theirsolutions serve two main markets: (1) Asset Tracking remote location tracking various assets such as trailers, dry vans etc., and (2) Connected Sensors of to remotely track sensors information on non-powered fixed and movable assets. BeWhere's devices use the latest available cellular technologies (LTE-M and NB-IoT) to transmit collected data into mobile applications and cloud-based platforms, at a much lower cost than traditional cellular networks. BeWhere also offer solutions that can be fully integrated with existing software, and white-labeled. BeWhere' solutions are cutting edge, offering low-cost sophisticated technology which allows customers to deploy remote tracking technology where cost was previously prohibitive. For more information, visit the company's website at:

BioCorRx Inc. (OTCQB: BICX)

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information, visit the company's website at:

Blackbird plc (OTCQX: BBRDF)

Blackbird plc (OTCQX: BBRDF) operates in the fast-growing SaaS and cloud video market. It has created Blackbird®, the world's most advanced suite of cloud-native computing applications for video, all underpinned by its lightning-fast codec. Blackbird plc's patented technology allows for frame accurate navigation, playback, viewing and editing in the cloud. Blackbird® enables multiple applications, which are used by rights holders, broadcasters, sports and news video specialists, esports, live events and content owners, post-production houses, other mass market digital video channels and corporations. For more information, visit the company's website at:

Boardwalktech Software (TSXV: BWLK) (OTCQB: BWLKF)

Boardwalktech Software (TSXV: BWLK) (OTCQB: BWLKF) has developed a patented Digital Ledger Technology Platform used by Fortune 500 companies running hundreds of live mission-critical applications worldwide. Boardwalktech's patented digital ledger technology and its unique method of managing vast amounts of structured and unstructured data is the only platform on the market today where multiple parties can effectively work on the same data simultaneously. Boardwalktech can deliver a collaborative purpose-built enterprise information management application on any device or user interface with full integration with enterprise systems of record in a fraction of the time it takes other non-digital ledger technology-based applications. For more information, visit the company's website at:

BrainChip Holdings Inc. (OTC: BRCHF) (ASX: BRN)

BrainChip Holdings (OTC: BRCHF) (ASX: BRN) develops software and hardware accelerated solutions for artificial intelligence (AI) and machine learning applications in North America, Europe, the Middle East, and Asia. It offers Akida Development Environment, a machine learning framework for creating, training, and testing neural networks, as well as supporting the development of systems for edge AI on its Akida event domain neural processor; and Akida Neuromorphic Processor to provide a ultra-low power and fast AI Edge Network for vision, audio, olfactory, and smart transducer applications. The company also provides Akida Neuromorphic System-on-Chip, an integrated solution for Edge AI device and systems. Its products are used in various applications, such as automotive and cybersecurity. The company has a research collaboration with Biotome Pty Ltd for SARS-CoV-2 antibody detection. BrainChip Holdings Ltd was incorporated in 2011 and is based in Sydney, Australia. For more information, visit the company's website at:

BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSXV: BCT)

BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX-V: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat (both provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first "off the shelf" personalized immunotherapy for advanced breast cancer. For more information, visit the company's website at:

Canagold Resources (OTCQB: CRCUF)

Canagold Resources (OTCQB: CRCUF) was founded by Bradford Cooke (Endeavour Silver), led by CEO Scott Eldridge, is advancing western Canada's highest grade gold deposit, New Polaris in BC, to feasibility. Current resource: 586 Moz gold Indicated (1.6mt @ 10.8 g/t Au); 485 Moz gold Inferred (1.4mt @ 10.2 g/t Au) (PEA grade 10.3 g/t Au with 20% dilution). NOW DRILLING a 24,000-metre, 47-drillhole program hit 24.2 g/t gold over 6.6 m and 15.8 g/t gold over 13.0 m, deep holes are forthcoming to test downdip extension to expand gold resources. For more information, visit the company's website at:

Candente Copper Corp. (TSX: DNT)

Candente Copper Corp. (TSX: DNT) a mineral exploration company, engages in the acquisition, exploration, and development of mineral properties. The company primarily explores for copper, gold, and silver deposits. Its principal property is the Cañariaco project consisting of 5 Cañariaco concessions covering a total area of 4,289.50 hectares located in Northern Peru. The company was formerly known as Candente Resource Corp. and changed its name to Candente Copper Corp. in December 2009. Candente Copper Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada. For more information, visit the company's website at:

Chalice Brands Ltd. (OTCQB: CHALF)

Chalice Brands (OTCQB: CHALF) is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with twelve dispensaries owned and four dispensaries under management in Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth & Root and has operations in Oregon and California. For more information, visit the company's website at:

Charah Solutions, Inc. (NYSE: CHRA)

Charah Solutions, Inc. (NYSE: CHRA) is a leading provider of environmental services and byproduct sales to the power generation industry. Based in Louisville, Kentucky, Charah Solutions assists utilities and independent power producers with all aspects to sustainably manage and recycle ash byproducts generated from the combustion of coal in the production of electricity. The Company also designs and implements solutions for ash pond management and closure, landfill construction, fly ash sales, and structural fill projects. Charah Solutions is the partner of choice for solving customers' most complex environmental challenges, and as an industry leader in quality, safety, and compliance, the Company is committed to reducing greenhouse gas emissions for a cleaner energy future. For more information, visit the company's website at:

CloudCall Group plc (OTCQX: CLLLF)

CloudCall (OTCQX: CLLLF) is a software and integrated communications business that has developed and provides a suite of cloud-based software and communications products and services. CloudCall's products and services are aimed at enabling organisations to leverage their customer data to enable more effective communications and improve performance. The CloudCall suite of software products allows companies to fully integrate telephony, messaging and contact centre capabilities into their existing customer relationship management (CRM) software, enabling communications to be made, recorded, logged and categorised from within the CRM system with detailed activity reporting and powerful business intelligence capable of being easily generated and used to enhance knowledge and improve customer experience. For more information, visit the company's website at:

DATA Communications Management Corp. (TSX: DCM)

DATA Communications Management Corp. (TSX: DCM) is a leading provider of marketing and workflow solutions that solve the complex branding, communications, logistics and regulatory challenges of some of North America's biggest brands. Powered by purpose-built technology like their DCMFlex™ workflow management platform and their ASMBL digital asset management solution, they help clients bring their brands to life and create more meaningful connections with customers. DCM serves market leaders in key verticals such as financial services, retail, cannabis, energy, and the public sector, supporting them with marketing scale, speed, efficiency and insight that drives their competitiveness and improves their performance. For more information, visit the company's website at:

Data Storage Corporation (NASDAQ: DTST)

Data Storage Corporation (NASDAQ: DTST) delivers and supports a broad range of premium technology solutions focusing on IaaS, data storage protection and IT management. Clients look to Data Storage to ensure disaster recovery, business continuity, enhance security, and to meet increasing industry, state and federal regulations. The Company markets to businesses, government, education and the healthcare industry by leveraging leading technologies. Through its business units, the Company provides IaaS, SaaS, DRaaS, VoIP, cyber security, data analytics, IBM Power systems and storage hardware with managed IT services. For more information, visit the company's website at:

Diamcor Mining Inc. (OTCQB: DMIFF) (TSXV: DMI)

Diamcor Mining Inc. (OTCQB: DMIFF) (TSX-V: DMI) has a proven history supplying rough diamonds to the world market. The Company has established a long-term strategic alliance with world famous luxury retailer Tiffany & Co. and is now in the final stages of completing a near-term production processing plant at their 100% owned Krone-Endora Project next door to De Beers flagship Venetia diamond mine. For more information, visit the company's website at:

Dynatronics Corporation (NASDAQ: DYNT)

Dynatronics Corporation (NASDAQ: DYNT) is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann™, Physician's Choice®, and PROTEAM™, among others. For more information, visit the company's website at:

Emmaus Life Sciences, Inc. (OTC: EMMA)

Emmaus Life Sciences, Inc. (OTC: EMMA is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases. Theirinitial efforts have focused on treatments for Sickle Cell Disease, a genetic disorder. Emmaus's lead commercial product is Endari®, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. For more information, visit the company's website at:

Enveric Biosciences Inc. (NASDAQ: ENVB)

Enveric Biosciences, Inc., (NASDAQ: ENVB) a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida. For more information, visit the company's website at:

FansUnite Entertainment Inc. (CSE: FANS) (OTCQX: FUNFF)

FansUnite Entertainment Inc. (CSE: FANS) (OTCQX: FUNFF) is a sports and entertainment company, focusing on technology related to regulated and lawful online sports betting and other related products. FansUnite runs sports betting brands and has developed a full-suite Gaming platform to provide its partners and players a versatile and vertically integrated platform with a portfolio of unique products focusing on esports, sports betting, and casino products. For more information, visit the company's website at:

Feldan Therapeutics

Feldan Therapeutics is a pre-clinical biotechnology company developing leading-edge treatments based on its proprietary peptide-based delivery technology, the Feldan Shuttle platform. The peptides of the Feldan Shuttle platform (the "Shuttles") deliver small molecules, proteins, and peptides inside cells in vivo in the context of direct injections/application, and ex vivo. The Shuttles can introduce active proteins and peptides intracellularly in different organs including the skin, eyes, lungs, muscles, brain and liver after local and systemic administration; moreover, delivery of active cargos by the technology leads to phenotypic changes, thus confirming the therapeutic potential of the technology. This new platform is a safe and highly efficient approach associated with low regulatory burden, characteristics that will facilitate the translation of Feldan's technology to the clinic. The Shuttles give access to a wide range of intracellular therapeutic targets that were thought to be undruggable, a breakthrough which will in turn lead to the generation of novel classes of drugs. Feldan's current focus is to bring to clinic a topical basal cell carcinoma treatment designed for Gorlin Syndrome patients and an intranasal CRISPR-nuclease-based cystic fibrosis application. For more information, visit the company's website at:

First Cobalt Corp. (TSXV: FCC)

First Cobalt Corp. (TSXV: FCC) mission is to be a producer of diversified high-quality and sustainable battery materials for the North American battery supply chain. The Company owns a permitted hydrometallurgical refinery in Ontario, Canada, a critical asset in the development and manufacturing of batteries for electric vehicles. First Cobalt also owns the Iron Creek cobalt-copper project in Idaho, USA as well as several significant cobalt and silver properties in the Canadian Cobalt Camp. For more information, visit the company's website at:

Focus Universal Inc. (NASDAQ: FCUV)

Focus Universal Inc. (NASDAQ: FCUV) is a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G. The company has developed four disruptive patented technologies to solve the major problems facing hardware design, hardware production, software design and network communication facing both industries today: (1) Universal Smart Instrumentation Platform; (2) Natural Integrated Programmable Language; (3) Ultra Narrowband Power Line Communications; (4) Ultra Narrowband Wireless Communication For more information, visit the company's website at:

GEE Group Inc. (NYSE: JOB)

GEE Group Inc. (NYSE: JOB) is a multi-brand national staffing and recruiting firm serving the IT, Legal, Engineering, Finance and Accounting and Healthcare segments by providing professional and commercial staffing services. For more information, visit the company's website at:

Harbor Custom Development, Inc. (NASDAQ: HCDI)

Harbor Custom Development, Inc. (NASDAQ: HCDI) is an innovative and market leading real estate development company involved in all aspects of the land development cycle including land acquisition, entitlements, construction of project infrastructure, home building, marketing, and sales of various single-family and condominium projects in Washington, California, Texas and Florida. Theyhave constructed single-family communities and homes in Gig Harbor, Bremerton, Silverdale, Bainbridge Island, Belfair, Allyn, and Port Orchard in the state of Washington, and have single-family homes and condominiums in various stages of development in California, Texas, and Florida. Theirbusiness strategy is focused on the acquisition of land to develop property for the construction and sale of residential lots, home communities, or condominium properties within a 30 to 60-minute commute to major metropolitan employment corridors. For more information, visit the company's website at:

HyreCar Inc. (NASDAQ: HYRE)

HyreCar Inc. (NASDAQ: HYRE) together with subsidiaries, operates a web-based car-sharing marketplace in the United States. Its marketplace allows car owners to rent their idle cars to ride-sharing service drivers, such as Uber and Lyft drivers. HyreCar Inc. was incorporated in 2014 and is headquartered in Los Angeles, California. For more information, visit the company's website at:

International Land Alliance Inc. (OTCQB: ILAL)

International Land Alliance, Inc. (OTCQB: ILAL) is an international land investment and development firm based in San Diego, California. As its core mission, the Company has embraced technology for sustainable and socially responsible solutions, in addition to using proptech and construction tech advanced applications to meet these goals. The Company is focused on acquiring attractive raw land primarily in Northern Baja California, often within driving distance from Southern California. The Company serves its shareholders by devoting considerable time and resources to seeking out the finest sites available and obtaining the necessary development permits to build a compelling portfolio of properties, which provide a diversity of investment and living options. For more information, visit the company's website at:

Khiron Life Sciences Corp. (OTCQX: KHRNF) (CVE: KHRN)

Khiron Life Sciences Corp. (OTCQX: KHRNF) (CVE: KHRN) is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors. For more information, visit the company's website at:

Kintara Therapeutics, Inc. (NASDAQ: KTRA)

Kintara Therapeutics, Inc. (NASDAQ: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC). For more information, visit the company's website at:

KULR Technology Group, Inc (NYSE American: KULR)

KULR Technology Group Inc. (NYSE American: KULR) develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic systems. Leveraging the company's roots in developing breakthrough cooling solutions for NASA space missions and backed by a strong intellectual property portfolio, KULR enables leading aerospace, electronics, energy storage, 5G infrastructure, and electric vehicle manufacturers to make their products cooler, lighter and safer for the consumer. For more information, visit the company's website at:

Lantern Pharma Inc. (NASDAQ: LTRN)

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. For more information, visit the company's website at:

Lifeist Wellness Inc. (TSXV: LFST)

Lifeist Wellness Inc. (TSXV: LFST) operates as a portfolio of companies focused on wellness. Through CannMart, the company operates 1), an online marketplace for medical cannabis products and accessories in Canada and hemp-derived CBD and smoking accessories in the United States, 2) CannMart Labs, a BHO extraction facility to produce cannabis concentrate products, and 3) CannMart Inc. which primarily sells cannabis products and accessories to provincial wholesalers and stand-alone businesses. The company is also set to launch a nutraceuticals division in the fourth quarter of 2021. Based in Vancouver, Canada, the company was formerly known as Namaste Technologies Inc. and changed its name to Lifeist Wellness Inc. in September 2021. For more information, visit the company's website at:

LiveXLive Media (NASDAQ: LIVX)

LiveXLive Media (NASDAQ: LIVX) is a global talent-first, interactive music, sports, and entertainment subscription platform delivering premium content and livestreams from the world's top artists. The Company has streamed over 1,800 artists since January 2020, a library featuring close to 30 million songs, 500 expertly curated radio stations, 235 podcasts/vodcasts, hundreds of pay-per-views, personalized merchandise, an NFT business, and has created a valuable connection between brands, fans, and bands. LiveXLive Media's other major wholly-owned subsidiaries are LiveXLive, Slacker Radio, React Presents, Custom Personalization Solutions, and PodcastOne, which generates more than 2.27 billion downloads per year and 300+ episodes distributed per week across a stable of hundreds of top podcasts. The combination of acquisitions and the expansion of products and franchises have secured LiveXLive as a top-rated music, entertainment and media services company. LiveXLive is available on iOS, Android, Roku, Apple TV, and Amazon Fire, and through OTT, STIRR, Sling, and XUMO, in addition to its app, online website, and social channels. For more information, visit the company's website at:

Lobe Sciences (OTC: GTSIF)

Lobe Sciences (OTC: GTSIF) is a life sciences company focused on psychedelic medicines. The Company is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness. The Company is mastering the development of transformational medicines and devices as they build a growing portfolio of intellectual property to support wellness and improve mental health. Theyfocus on clinical development of devices and medicines to treat specific medical conditions and brain traumas. Additionally, generating ongoing cash flow from licensing and other agreements. For more information, visit the company's website at:

Mace Security International (OTCQX: MACE)

Mace Security International (OTCQX: MACE) is a globally recognized leader in personal safety and security. Based in Cleveland, Ohio, the company has spent more than 40 years designing and manufacturing consumer and tactical products for personal defense and security under its world-renowned Mace® Brand – the original trusted brand of defense spray products. The company also offers aerosol defense sprays and tactical products for law enforcement and security professionals worldwide through its Mace® Take Down® brand, KUROS!® Brand personal safety products, and Tornado® Brand pepper spray and stun guns. MACE® distributes and supports Mace® Brand products through mass market retailers, wholesale distributors, independent dealers,,, and other channels. For more information, visit the company's website at:

ME2C Environmental (OTCQB: MEEC)

ME2C Environmental (OTCQB: MEEC) is a leading environmental technologies company developing and delivering patented and proprietary solutions to the global power industry. ME2C's leading-edge services have been shown to achieve emissions removal at a significantly lower cost and with less operational impact than currently used methods while maintaining and/or increasing power plant output and preserving the marketability of byproducts for beneficial use. ME2C Environmental is a trade name of Midwest Energy Emissions Corp. For more information, visit the company's website at:

Mechanical Technology, Incorporated (NASDAQ: MKTY)

Mechanical Technology, Incorporated (NASDAQ: MKTY) is the parent company of MTI Instruments, Inc. and EcoChain, Inc. Through EcoChain, MTI develops cryptocurrency mining facilities powered by renewable energy that integrate with the blockchain network. Through MTI Instruments, MTI is engaged in the design, manufacture and sale of test and measurement instruments and systems that use a comprehensive array of technologies to solve complex, real-world applications in numerous industries. Those include manufacturing, electronics, semiconductor, solar, commercial and military aviation, automotive and data storage. For more information, visit the company's website at:

Medexus Pharma (TSX: MDP) (OTCQX: MEDXF)

Medexus Pharma (TSX: MDP) (OTCQX: MEDXF) is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products theyare building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin theirgrowth for the next decade. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through theircore values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of hematology, auto-immune disease, and allergy. The Company's leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. The Company has also licensed treosulfan, a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, from medac GmbH for Canada and the United States. For more information, visit the company's website at:

Metamaterial Inc. (NASDAQ: MMAT)

Meta Materials Inc. (NASDAQ: MMAT) is a smart materials and photonics company, invents, designs, develops, and manufactures various functional materials and nanocomposites. META® delivers previously unachievable performance, across a range of applications, by inventing, designing, developing, and manufacturing sustainable, highly functional materials. Theirextensive technology platform enables leading global brands to deliver breakthrough products to their customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. Theirachievements have been widely recognized, including being named a Global Cleantech 100 company. The company is headquartered in Dartmouth, Canada with office in the UK and US. For more information, visit the company's website at:

Mitesco, Inc. (OTCQB: MITI)

Mitesco, Inc. (OTCQB: MITI) is a growth-oriented holding company focused on delivering consumer-oriented healthcare services and solutions. Theirmission is to improve consumers' quality of life by delivering personalized care, improving human interaction within healthcare and meeting people's needs as a "whole person". Theyseek to leverage the seamless intersection of healthcare and technology to increase quality and reduce cost of care, while enhancing consumer convenience. For more information, visit the company's website at:

mPhase Technologies, Inc. (OTC Pink: XDSL)

mPhase Technologies, Inc. (OTC Pink: XDSL) is an emerging EV-centric technology company focused on consumer engagement using data analytics and artificial intelligence to create a monetizable link between consumers and retailers at opportunistic times and places. The Company is currently building a connected ecosystem of EV charging, 5G internet connectivity and software solutions that optimize consumer engagement within the framework of a SaaS/TaaS model. Branded under the mPower name, this ecosystem will empower the way people shop, dine, fuel and interact with the world to create a richer life experience. The mPower ecosystem is tailored to each individual's tastes and needs, with particular emphasis on empowering tomorrow's green consumer. mPhase also has data driven business units generating recurring revenue outside of its consumer ecosystem, in addition to legacy nanobattery technology and a related patent portfolio that are slated for future development. For more information, visit the company's website at:

Nephros, Inc. (NASDAQ: NEPH)

Nephros, Inc. (NASDAQ: NEPH) a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey. For more information, visit the company's website at:


Neurosom® has invented a proprietary Sleep Therapy technology that has been proven to extend deep sleep. Recent scientific evidence has shown that crucial processes such as brain waste clearance occur during deep sleep. Deep sleep tends to decrease as we age. Extending and improving deep sleep gives theirbodies the healthful benefits we need for good self-care. Neurosom® is a subsidiary of BEL, (Brain Electrophysiology Laboratory). Neurosom® wholly owns the patent protection for proprietary slow oscillation targeting.

Nova Leap Health Corp. (TSXV: NLH)

Nova Leap Health Corp. (TSXV: NLH) is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #2 ranking on the 2020 Report on Business ranking of Canada's Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 7 different U.S. states within the New England, South- Central and Midwest regions as well as Nova Scotia, Canada. For more information, visit the company's website at:

Origin Agritech Limited (NASDAQ: SEED)

Origin Agritech Limited (NASDAQ: SEED), together with its subsidiaries, operates an agricultural biotechnology and an e-commerce platform in the People's Republic of China. The company engages in crop seed breeding and genetic improvement activities. It develops, produces, and distributes hybrid crop seeds, as well as develops hybrid seed technology. The company also operates an e-commerce platform, which provides range of products, including agricultural seed products that comprise corn, rice, and vegetable seeds; other agricultural inputs, such as fertilizers and agricultural chemicals; foods; household products; and other consumer products to farmers through online and mobile ordering. It has a collaboration agreement with China Agricultural University for the research of molecular design in corn. Origin Agritech Limited was founded in 1997 and is headquartered in Beijing, China. For more information, visit the company's website at:

Perimeter Medical Imaging (TSXV: PINK) (OTC: PYNKF)

Perimeter Medical Imaging (TSXV: PINK) (OTC: PYNKF) is a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional, real-time margin visualization 1-2 mm below the surface of an excised tissue specimen. This OCT imaging system consists of S-series OCT, B-series OCT, and OCT imaging console. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers tissue immobilization system, a single use consumable, aids in positioning diverse tissue types; and proprietary image library, a broad based tissue library with pathology verified tissues structure correlations. Perimeter Medical Imaging AI, Inc. was founded in 2013 and is headquartered in Toronto, Canada. For more information, visit the company's website at:

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI)

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) aims to be a premiere Men's Health therapeutics company, prescription and over-the-counter (OTC), with a currently commercialized multi-product asset portfolio and a pre-clinical asset in development for the potential treatment of Peyronie's disease. For more information, visit the company's website at:

Pluristem Therapeutics Inc. (NASDAQ: PSTI)

Pluristem Therapeutics Inc. (NASDAQ: PSTI) operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel. For more information, visit the company's website at:

ProMIS Neurosciences, Inc. (OTC: ARFXF) (TSX: PMN)

ProMIS Neurosciences, Inc. (OTC: ARFXF) (TSX: PMN), a development stage biotech company, discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prion-like forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. For more information, visit the company's website at:

ProPhase Labs (NASDAQ: PRPH)

ProPhase Labs (NASDAQ: PRPH) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and also build a genomics data base to be used for further research including clinical studies. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. ProPhase Precision Medicine, Inc., focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. For more information, visit the company's website at:

PyroGenesis Canada Inc. (TSX: PYR)

PyroGenesis Canada Inc. (TSX: PYR), a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and sustainable solutions which reduce greenhouse gases (GHG), and are economically attractive alternatives to conventional "dirty" processes. PyroGenesis has created proprietary, patented and advanced plasma technologies that are being vetted and adopted by multiple multibillion dollar industry leaders in four massive markets: iron ore pelletization, aluminum, waste management, and additive manufacturing. With a team of experienced engineers, scientists and technicians working out of its Montreal office, and its 3,800 m2 and 2,940 m2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The operations are ISO 9001:2015 and AS9100D certified, having been ISO certified since 1997. For more information, visit the company's website at:

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) is a biopharmaceutical company specializing in aerosol delivery of drugs and supplements that has developed a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary patent pending formula of one or more cannabinoid compounds, including Cannabidiol (CBD). This medical technology delivers medication directly to a user's blood stream through the pulmonary tract. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Addison, Texas. For more information, visit the company's website at: Group Inc. (NASDAQ: RCRT) (NASDAQ: RCRTW) Group Inc. (NASDAQ: RCRT) (NASDAQ: RCRTW) is a recruiting solutions platform that helps employers solve their unique hiring challenges. The company offers employers software subscription services to receive qualified and interested candidates, as well as on-demand hiring help from a network of professional recruiters. It also provides recruitment marketing through its talent communities. is dedicated to transforming recruiting with on-demand technology-based solutions that flex with hiring needs. The company was incorporated in 2015 and is based in New York, New York. For more information, visit the company's website at:

Red Cat Holdings, Inc. (NASDAQ: RCAT)

Red Cat Holdings, Inc. (NASDAQ: RCAT), together with its subsidiaries, provides products, services, and solutions to the drone industry. The company offers First Person View (FPV) video goggles to the drone industry. It also sells FPV drones and equipment, primarily to the consumer marketplace through its digital storefront located at In addition, the company offers software and hardware solutions that enable drones to complete inspection services in locations where GPS is not available. Further, it is developing a Software-as-a-Solution platform to provide drone flight data analytics and storage, as well as diagnostic products and services. Red Cat Holdings, Inc. was incorporated in 1984 and is based in Humacao, Puerto Rico. For more information, visit the company's website at:

Renavotio, Inc. (OTCQB: RIII)

Renavotio, Inc. (OTCQB: RIII) focuses on three unique infrastructure opportunities, including medical protective equipment, 5G, ISP, utility construction, utility management, IoT, water, waste management technology, and related industries. Their wholly owned subsidiary, Renavotio Infratech, Inc. ("RII"), includes business and acquisition strategies concentrating on medical protective equipment and infrastructure with utility construction and consulting/operational agreements with small towns or county CO-OPS that operate their own water and sewer systems, providing long-term savings, utilizing smart-utility monitoring, and dedicated engineering and service personnel. These platforms capture utility data from hand-held GPS devices or in-place sensors, with planned use of drones to identify waste contamination, leak detection, and topographic underground utility installation planning. RII's wholly owned subsidiary, Utility Management Corp, is a holding company focused on infrastructure, 5G, utility construction, utility management, IoT, water and waste management technology, and related industries. Utility Management Corp's subsidiary, Utility Management and Construction (UMCCO) is an engineering and smart utility management company that provides a one-stop solution to rural communities to reduce the consumption of electricity, data, natural gas, and water utilities for commercial, industrial and municipal end users. UMCCO's unique approach creates immediate bottom-line savings for its clients, by providing engineering, planning, permitting and installation through their second wholly owned subsidiary, Cross-Bo Construction, which specializes in water, sewer, Telcom, and 5G design and installation, establishing a long-term value proposition while also achieving respective sustainability goals. For more information, visit the company's website at:

Riley Exploration Permian, Inc. (NYSE: REPX)

Riley Exploration Permian, Inc. (NYSE: REPX), an independent oil and natural gas company, engages in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids primarily in the Permian Basin. The company activities are primarily focused on the San Andres Formation, a shelf margin deposit on the Central Basin Platform and Northwest Shelf. Its acreage is primarily located on contiguous blocks in Yoakum County, Texas; and Lea, Roosevelt, and Chaves Counties, New Mexico. The company is based in Oklahoma City, Oklahom. For more information, visit the company's website at:

Safehold Inc. (NYSE: SAFE)

Safehold Inc. (NYSE: SAFE) is revolutionizing real estate ownership by providing a new and better way for owners to unlock the value of the land beneath their buildings. Through its modern ground lease capital solution, Safehold helps owners of high quality multifamily, office, industrial, hospitality and mixed-use properties in major markets throughout the United States generate higher returns with less risk. The Company, which is taxed as a real estate investment trust (REIT) and is managed by its largest shareholder, iStar Inc., seeks to deliver safe, growing income and long-term capital appreciation to its shareholders. For more information, visit the company's website at:

Salem Media Group, Inc. (NASDAQ: SALM)

Salem Media Group, Inc. (NASDAQ: SALM) is America's leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing.Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally.With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. For more information, visit the company's website at:

Sigyn Therapeutics, Inc. (OTCPK: SIGY)

Sigyn Therapeutics, Inc. (OTCPK: SIGY) Sigyn Therapeutics™ is focused on significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. The annual market opportunity exceeds $20 billion. Sigyn Therapy™ is a multifunctional blood purification technology designed to mitigate the Cytokine Storm that underlies Sepsis (the #1 cause of in-hospital deaths) and other high-mortality inflammatory disorders commonly induced by bacterial and viral pathogens. To overcome the limitations of previous therapies, Sigyn Therapy addresses the source of inflammation (viral pathogens, bacterial toxins) in concert with the broad-spectrum depletion of inflammatory cytokines from the bloodstream. Additionally, the device establishes a therapeutic strategy to target CytoVesicles that transport inflammatory cargos throughout the circulatory system. For more information, visit the company's website at:

Snipp Interactive Inc. (TSXV: SPN) (OTCPK: SNIPF)

Snipp Interactive Inc (TSX-V: SPN) (OTCPK: SNIPF) is a Platform-as-a-Service (PaaS) company in the global loyalty and promotions sector. Snipp's proprietary and modular SnippCARE (Customer Acquisition, Retention & Engagement) Platform allows its marquee list of Fortune 1000 Clients and world-class agencies and partners to use various modules of the Platform to run long-term and short-term programs and promotions, while continually generating and capturing unique zero party data that is invaluable in providing insights to drive sales. SnippCHECK, the Platform's Receipt Processing Module has established itself as the clear industry leader and standard by powering a large majority of all receipt based promotions in North America. SnippLOYALTY, the Platform's full scale modular loyalty engine allows clients the flexibility of deploying any/all aspects of a standard loyalty program on a case by case basis. SnippREWARDS, the Platform's modular catalogue of digital and physical rewards provides Clients with global and easily deployable access to an extensive catalogue of digital and physical rewards. SnippWIN, the Platform's gaming module solves for the implementation and compliance difficulties of offering games of chance and skill on a global basis, and allows for the global deployment and administration of legally compliant games of chance and skill. For more information, visit the company's website at:

Spectral Medical Inc. (TSX: EDT)

Spectral Medical Inc. (TSX: EDT) Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year. For more information, visit the company's website at:

StoneCastle Financial Corp. (NASDAQ: BANX)

StoneCastle Financial Corp. (NASDAQ: BANX) is a closed end investment management company.The Company makes banking-related investments including money-center, regional and community banks, and other FDIC-insured institutions. StoneCastle's primary investment objective is income generation. StoneCastle has a dividend yield of approximately 7%. The Company is focused on capital preservation, and credit quality, providing risk-adjusted total return. StoneCastle's strategy is to invest in term loans, structured debt, regulatory capital, trust preferred/preferred securities, making long-term passive investments. The Company issues a monthly Net Asset Value (NAV) and hosts a quarterly conference call. The Company's leverage is limited to 33.33% as a regulated investment company. ArrowMark Partners, acquired certain assets and took over the management of StoneCastle under StoneCastle-ArrowMark Asset Management, LLC. ArrowMark Partners, with ~$20B AuM, offers a deep bench of financial and human capital dedicated to the Company. StoneCastle Financial Corp. is located in Denver, CO. For more information, visit the company's website at:

Tego Cyber Inc. (OTCQB: TGCB)

Tego Cyber Inc. (OTCQB: TGCB) was created to capitalize on the emerging cyber threat intelligence market. Tego Cyber Inc. has developed a cyber threat intelligence application that integrates with top end security platforms. The Tego Threat Intelligence Platform (TTIP) takes in vetted and curated threat data and after utilizing a proprietary process, the platform compiles, analyzes, and then delivers that data to an enterprise network in a format that is timely, informative, and relevant. For more information, visit the company's website at:

The Andersons (NASDAQ: ANDE)

The Andersons (NASDAQ: ANDE) was founded in Maumee, Ohio, in 1947, The Andersons is a diversified company rooted in agriculture, conducting business across North America in the commodity trading, ethanol, and plant nutrient sectors. Through its Statement of Principles, The Andersons strives to provide extraordinary service to its customers, help its employees improve, support its communities, and increase the value of the company. For more information, visit the company's website at:

Thermal Energy International (TSXV: TMG) (OTC: TMGEF)

Thermal Energy International (TSXV: TMG) (OTC: TMGEF) ranked as one of Canada's Top Growing Companies in 2021, 2020 and 2019, is an established global supplier of proprietary, proven energy efficiency and emissions reduction solutions to the industrial and institutional sectors. They are saving their customers money and improve their bottom line by reducing their fuel use and cutting their carbon emissions. Theircustomers include many Fortune 500 and other leading multinational companies across a wide range of industry sectors. Thermal Energy is a fully accredited professional engineering firm and by providing a unique mix of proprietary products together with process, energy, and environmental engineering expertise, Thermal Energy can deliver unique turnkey projects with significant financial and environmental benefits for theircustomers. For more information, visit the company's website at:

Tonix Pharmaceuticals (NASDAQ: TNXP)

Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The Company's CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia. Tonix's immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-18002, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. For more information, visit the company's website at:

Tower One Wireless Corp. (CSE: TO) (OTCQB: TOWTF)

Tower One Wireless Corp. (CSE: TO) (OTCQB: TOWTF) principal business is to build, own and operate multi-tenant wireless telecommunications infrastructure ("towers") in Latin America. Tower One leases space on its towers to mobile network operators. The Company is focused on the build to suit tower industry whereby a long-term lease is secured with a tenant prior to building a tower. The Company owns and operates 172 towers in the two largest Spanish speaking countries in Latin America (Colombia and Mexico) with a combined population of approximately 180 million people. For more information, visit the company's website at:

Townsquare Media Inc. (NYSE: TSQ)

Townsquare Media Inc. (NYSE: TSQ) is a community-focused digital media, digital marketing solutions and radio company focused outside the Top 50 markets in the U.S. Theirassets include Townsquare Interactive, a digital marketing services subscription business providing websites, search engine optimization, social platforms and online reputation management for approximately 24,950 SMBs; Townsquare IGNITE, a proprietary digital programmatic advertising technology with an in-house demand and data management platform; and Townsquare Media, theirportfolio of 322 local terrestrial radio stations in 67 cities with corresponding local news and entertainment websites and apps including legendary brands such as,, and along with a network of national music brands including,, and For more information, visit the company's website at:

TransCode Therapeutics, Inc. (NASDAQ: RNAZ)

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is The RNA Oncology Company, TransCode is committed to defeating cancer through the intelligent design and effective delivery of regulatory and messenger RNA. Theirmodular toolbox enables rational drug design, exemplified by theirlead Therapeutic Candidate TTX-MC138 which targets miR-10b for the treatment of metastatic cancer. Research & Development efforts are focused on expanding theirdelivery capabilities in RNAi as well as RIG-I, CRISPR, and mRNA. For more information, visit the company's website at:

Ur-Energy Inc. (NYSE: URG) (TSX: URE)

Ur-Energy Inc. (NYSE: URG) (TSX: URE) is a uranium mining company operating the Lost Creek in-situ recovery uranium facility in south-central Wyoming. Theyhave produced, packaged and shipped approximately 2.6 million pounds from Lost Creek since the commencement of operations. Applications are under review by WDEQ-LQD to incorporate their LC East project area into the Lost Creek permits and by various agencies to construct and operate at their Shirley Basin Project. Ur-Energy is engaged in uranium mining, recovery and processing activities, including the acquisition, exploration, development and operation of uranium mineral properties in the United States. Shares of Ur Energy trade on the NYSE American under the symbol "URG" and on the Toronto Stock Exchange under the symbol "URE." Ur-Energy's corporate office is in Littleton, Colorado; its registered office is in Ottawa, Ontario. For more information, visit the company's website at:

VersaBank (TSX: VB) (NASDAQ: VBNK)

VersaBank (TSX: VB) (NASDAQ: VBNK) is a schedule I chartered bank, provides banking products and services in Canada. The company offers deposit products, such as guaranteed investment certificates, registered retirement savings plans, daily interest savings accounts, and tax-free savings accounts, as well as deposit insurance; and commercial lending services, including short-term construction financing, long-term financing, and loan refinance and lease buy out to real estate developers and condominium corporations in selective niche markets. It also purchases loan and lease receivables from finance companies. The company was formerly known as Pacific & Western Bank of Canada and changed its name to VersaBank in May 2016. VersaBank was founded in 1979 and is headquartered in London, Canada. For more information, visit the company's website at:

Vertical Capital Income Fund (NYSE: VCIF)

Vertical Capital Income Fund (NYSE: VCIF) is an NYSE-listed closed-end fund that seeks monthly income by investing primarily in performing non-agency residential whole loans secured by real estate. As a secondary strategy the Fund aims to provide total return by acquiring performing residential loans at a discount to the unpaid principal balance (UPB). VCIF realizes capital gains as loans are paid off before maturity. For more information, visit the company's website at:

Vivos Therapeutics, Inc. (NASDAQ: VVOS)

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos' oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists. For more information, visit the company's website at:

VolitionRx Limited (NYSE: VNRX)

VolitionRx Limited (NYSE: VNRX) is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market. For more information, visit the company's website at:

Vyant Bio, Inc. (NASDAQ: VYNT)

Vyant Bio, Inc. (NASDAQ: VYNT) has developed a drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise. Through multiple in silico, in vitro, and in vivo modalities, Vyant Bio rapidly identifies and designs small and large molecule therapeutics that are derisked in human biology much earlier, and have lower costs and failure rates compared to traditional discovery platforms. The Company is focused on efficiently discovering neurology and oncology drugs and, going forward, plans to file two investigational new drug applications annually. Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia. The Company has five state-of-the-art labs and a scientific team with world experts in key areas who have been involved in over 200 investigational new drug applications and over 50 CNS and oncology studies and trials. For more information, visit the company's website at:

XPhyto Therapeutics Corp. (OTCQB: XPHYF) (CSE: XPHY)

XPhyto Therapeutics Corp. (OTCQB: XPHYF) (CSE: XPHY) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company's website at:

Ynvisible Interactive Inc. (TSXV: YNV) (OTCQB: YNBYF)

Ynvisible Interactive Inc. (TSXV: YNV) (OTCQB: YNBYF) is a leading company in the emerging printed and flexible electronics sector. Printed electronics are a key enabler of mass adoption of the Internet of Things ("IoT") and smart objects, given the cost and power consumption advantages over conventional electronics. Ynvisible Interactive's core market segments are Medical Devices, Supply Chain & Logistics and Premium Consumer Goods and Toys. Ynvisible is also a Contract Development and Printing Scale-Up supplier to emerging companies in the printed electronics and energy storage sectors. Ynvisible Interactive Inc. is headquartered in Vancouver, Canada. For more information, visit the company's website at:

Let's get started.

Interested in a live, online demonstration? Schedule a date and time that works for you.

Schedule a LIVE Demo

Questions about IBN and our solutions? Call or send us an email.

(310) 299-1717